Our previous study showed that the novel proteasome inhibitor NPI-0052 induces apoptosis in multiple myeloma (MM) cells resistant to conventional and bortezomib (Velcade TM 2 ) therapies. In vivo studies using human MMxenografts demonstrated that NPI-0052 is well tolerated, prolongs survival, and reduces tumour recurrence. These preclinical studies provided the basis for an ongoing phase-1 clinical trial of NPI-0052 in relapsed/refractory MM patients. Here we performed pharmacodynamic (PD) studies of NPI-0052 using human MM xenograft murine model. Our results showed that NPI-0052: (i) rapidly left the vascular compartment in an active form after intravenous (i.v.) administration, (ii) inhibited 20S proteasome chymotrypsin-like (CT-L, b5), trypsin-like (T-L, b2), and caspase-like (C-L, b1) activities in extravascular tumours, packed whole blood (PWB), lung, liver, spleen, and kidney, but not brain and (iii) triggered a more sustained (>24 h) proteasome inhibition in tumours and PWB than in other organs (<24 h). Tissue distribution analysis of radiolabeled compound ( 3 H-NPI-0052) in mice demonstrated that NPI-0052 left the vascular space and entered organs as the parent compound. Importantly, treatment of MM.1S-bearing mice with NPI-0052 showed reduced tumour growth without significant toxicity, which was associated with prolonged inhibition of proteasome activity in tumours and PWB but not normal tissues.
Protein degradation regulates normal cellular homeostasis through a multi-subunit complex called the proteasome (Goldberg, 2003; Adams, 2004) . Pioneering studies by another group showed that ATP-dependent conjugation of proteins with polypeptide (ubiquitin) mediated protein degradation (Ciehanover et al, 1978; Ciechanover et al, 1980a Ciechanover et al, ,b, 1984 Hershko et al, 1980) . The 26S proteasome complex (Wilk & Orlowski, 1983; Hough et al, 1987; Waxman et al, 1987) consists of 19S units and a 20S proteasome core (Arrigo et al, 1988; Ganoth et al, 1988) ; the 19S units regulate entry of ubiquitinated proteins into the 20S core chamber (Peters et al, 1994; Goldberg, 2003) . Protein ubiquitination occurs via ATPdependent complex enzymatic reactions involving E1 and E2 ubiquitin enzymes, as well as E3 ubiquitin ligases. Recognition of ubiquitinated proteins by the 19S regulatory subunits allows for entry and degradation of proteins into small peptides of 4-20 amino acids. Proteasomal activities residing within the 20S core complex i.e., chymotrypsin-like (CT-L, b5), trypsinlike (T-L, b2), and caspase-like (C-L, b1), are responsible for protein degradation (Arendt & Hochstrasser, 1997) . Importantly, to date, many human diseases have been linked to defects in the ubiquitin-proteasome signalling (UPS) pathway (Adams, 2004) , suggesting the clinical utility of targeting proteasomes.
Our preclinical and clinical studies provided the basis for the US Federal Drug Administration approval of the first in class proteasome inhibitor bortezomib (Velcade TM ), for the treatment of relapsed/refractory, relapsed, and newly diagnosed MM (Hideshima et al, 2001; Kane et al, 2003; Richardson et al, 2003 Richardson et al, , 2005 Adams, 2004; San Miguel et al, 2008) . As with other agents, however, dose-limiting toxicities and the development of resistance limits its long-term utility Richardson et al, 2006 Richardson et al, , 2007 . Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 (Feling et al, 2003) (Chauhan et al, 2005) . These preclinical data provided the basis for an ongoing phase-1 clinical trial of NPI-0052 in relapsed/refractory MM patients.
In the present study, we utilized our human MM xenograft mouse model to define the distribution profile of NPI-0052 in various tissues and tumour, and in parallel analysed the kinetics of proteasome inhibition. Our data showed that NPI-0052 rapidly distributed from the vascular compartment into tumour and organs, associated with both prolonged proteasome inhibition in tumours and PWB and a marked delay in tumour growth.
Material and methods 3
Cell culture Human MM.1S MM cells were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA), and grown in RPMI-1640 media supplemented with 10% heat-inactivated fetal-bovine serum, 100 units/ml penicillin, 100 lg/ml streptomycin, 2 mmol/l L-glutamine, and plasmocin TM (10 lg/ml), as previously described (Chauhan et al, 2005) . Prior to inoculation of MM.1S cells in severe combined immunodeficient (SCID) mice, cell viability was assessed by trypan blue exclusion assay, as previously described (Chauhan et al, 2008 
Human plasmacytoma xenograft model
Animal studies were approved by the DFCI Institutional Animal Care and Use Committee. CB-17 SCID-male mice (4-6 weeks old) were purchased from Charles River Laboratories (Willminghton, MA, USA) and housed for 1-2 weeks before starting experiments. Tumours were established by subcutaneous injection of MM.1S cell line (5AE0 · 10 6 MM.1S cells in 100 ml of serum free RPMI-1640 medium, viability >99%) in the flank region of CB-17 SCID-male mice. The mice were divided into three different groups: Groups 1 and 2 (25 mice per group) for pharmacodynamics (PD) studies (time course) and Group 3 (10 mice) for drug efficacy studies. Tumour size was measured every third day in two dimensions using callipers, and tumour volume was calculated using the formula V =0 AE5 a · b 2 , where a and b are the long and short diameter of the tumour, respectively.
Treatment and dose schedule for PD and efficacy studies
The PD effects of NPI-0052 were assessed by measuring alterations in proteasome activity as a function of increasing exposure times and dose levels of NPI-0052. For the PD studies, mice were treated with vehicle or maximum tolerated dose (MTD) of NPI-0052 (i.v.) when tumours were 200-300 mm 3 .
Our prior study (Chauhan et al, 2005) established the MTD of NPI-0052 and we have used both single and repeated dosing (three dose) in the present study. For the measurement of proteasome activity, mice were euthanized at 10 min, 1, 4, and 24 h after NPI-0052 dosing. Liver, spleen, lung, kidney, brain and tumour were removed, immediately frozen on dry ice, and subsequently processed for determination of ex vivo proteasome activity. PWB was collected into tubes containing heparin from cardiac puncture. For efficacy studies, mice were treated i.v. with vehicle or NPI-0052 (0AE15 mg/kg) twice a week for 3 weeks. NPI-0052 was administered via the i.v. route at a dose of 0AE15 mg/kg either once (D1 for proteasome inhibition), three times (D1, D4, D8 for proteasome inhibition), or six times (D1, D4, D8, D11, D15, D18, for efficacy). for 10 min at 4°C. The supernatant was decanted, and formic acid (45%) added to the extracts, frozen at £60°C, and then analysed for total radioactivity and NPI-0052 concentrations. Based on the total radioactivity content, the extracts were pooled to obtain a minimum of 15 000 dpm for injection onto the YMC Pro C18 HPLC column. Using the relative retention time for authentic 3 H-NPI-0052, the chromatographic peak signal was integrated as a percentage of the total radioactivity chromatographed. Using the specific activity of the dose, the ng-equivalents percentage of 3 H-NPI-0052 was calculated. Male SpragueDawley rats were administered 3 H-NPI-0052 (0AE1 mg/kg or 0AE6 mg/m 2 ) by i.v. injection and at predetermined time points (n = 1 per time point) euthanized by deep isoflurane anaesthesia and subsequent submergence in a hexane/dry ice bath for 15 min, then removed and placed on dry ice (experiments performed at MPI Research, Mattawan, MI, USA). For Quantitative Whole Body Autoradiography (QWBA) (QPS, Newark, DE, USA), the frozen rat carcass was embedded in 2% carboxymethylcellulose, mounted on a microtome stage (Leica CM3600 Crymacrocut) and sections (approximately 40 lm thick) were prepared in the sagittal plane. The sections were placed on Scotch tape, dried, mounted on cardboard, and exposed to a 3 H-sensitive phosphor imaging plate (Fuji Biomedical, Stamford, CT, USA) for 7 d in light-tight cassettes, followed by scanning using the Typhoon 9410 TM image acquisition system (GE Healthcare, Sunnyvale, CA, USA).
Treatment and dose schedule

Protein extract preparation
After thawing, tissue samples (liver, lung, brain, kidney, tumour) were homogenized in 1 ml of lysis buffer (0AE5 mmol/l EDTA, pH 7AE3, 20 mmol/l HEPES, Triton X 100 0AE05%) and centrifuged at 14 000 rpm 5 for 30 min at 4°C. Supernatants were collected, and protein concentrations were determined using Bradford assay kit (Pierce, Rockford, IL, USA). Whole blood and splenocytes (obtained after slow mechanical disruption) were first washed with phosphatebuffered saline (PBS); RBCs were then lysed in 5 ml of red blood cell lysis buffer (Sigma, St. Luis, MO, USA) for 5 min at room temperature, followed by washing twice with PBS and lysis in lysis buffer (0AE5 mmol/l EDTA, pH 8AE0, 20 mmol/l HEPES, Triton X 100 0AE05%). Supernatants were collected, and protein concentrations were determined using the Bradford assay kit (Pierce, Rockford, IL, USA).
Proteasome activity assays
20S proteasome activity assays were performed using fluorogenic peptide substrates, as previously described (Lightcap et al, 2000; Chauhan et al, 2005) . 20 lg of protein was used in a total volume of 200 ll for determination of 20S proteasome CT-L, T-L or C-L activity, as described for the in vitro 20S proteasome activity assays with these exceptions: (i) the assay buffer consisted of 20 mmol/l HEPES, 0AE5 mmol/l EDTA, pH. 8AE0, (ii) the substrate used for determination of T-L activity was BZ-VGR-AMC, (iii) the final substrate concentration was 60 lmol/l and (iv) the assay buffer was supplemented with a final concentration of 0AE05% sodium dodecyl sulphate (SDS) for the evaluation of CT-L and the C-L activities. Data are presented as % inhibition compared to vehicle control treated animals.
In situ detection of apoptosis, and immunohistochemical (IHC) assessment of microvessel density (MVD)
Apoptotic cells in xenografted MM.1S tumours were identified by IHC staining for caspase-3 activation (Chauhan et al, 2008) . Microvessel density (MVD), a measure of tumour angiogenesis, was assessed by IHC staining for Factor VIII, as previously described (Chauhan et al, 2005 (Chauhan et al, , 2008 .
Western blotting
Total protein lysates were prepared and immunoblot blot analysis was performed, as previously described (Chauhan et al, 2005) . Briefly, equal amounts of proteins were resolved by 10% or 12AE5% SDS-polyacrylamide gel electrophoresis, and transferred onto nitrocellulose membranes. Filters were blocked by incubation in 5% dry milk in PBST (0AE05% Tween-20 in PBS) and probed with anti-Caspase-3, anti-PARP, anti-BIP, anti-pEIF2a, Hsp70, CHOP/GADD153, or anti-GAPDH Abs. Specific immunoreactive bands were detected by staining with HRP-conjugated secondary Abs, and blots were developed by enhanced chemiluminesence (ECL; Amersham, Arlington Heights, IL, USA).
Statistical analysis
Statistical significance of differences observed in untreated mice versus mice treated with NPI-0052 for various time periods was determined using a Student's t-test. The minimal level of significance was P <0 AE05.
Results
Pharmacodynamic (PD) effect of NPI-0052
MM.1S tumour-bearing mice were treated with either a single (D1) or three (D1, D4, and D8) doses of NPI-0052 (0AE15 mg/kg, i.v.), and euthanized at 10 min, 1, 4 and 24 h after dosing. PWB, liver, spleen, lung, kidney, brain and tumours were harvested, and analysed for CT-L, C-L, and T-L proteasome activities. Results showed significant inhibition of CT-L, C-L, and T-L proteasome activities in tumours and in these tissues, albeit with differential kinetics (Fig 1) . A time course analysis of proteasome activity in response to a single dose treatment of mice showed that: (i) NPI-0052 inhibited all three proteasome 3   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 activities in PWB, liver, spleen, lung, and kidney within 10 min, (ii) inhibition of proteasome activities occurred in tumours by 1 h and was maximal at 24 h, (iii) NPI-0052 did not inhibit proteasome activity in brain tissue and (iv) proteasome activities returned to baseline within 24 h in all tissues examined, except PWB and tumours (Fig 1) . These findings demonstrated that NPI-0052 rapidly left the vascular compartments, and targeted liver, spleen, lung, and kidney as early as 10 min. Importantly, NPI-0052-triggered a more sustained inhibition of proteasome activities in tumours and PWB than in other tissues.
We next examined alterations in proteasome activity profiles in various tissues in response to the treatment with three doses of NPI-0052. As seen in Fig 2, our results showed that: (i) all three proteasome activities were significantly inhibited (65-90%) in tumours and PWB, as well as in other tissues except brain within 10 min following the third dose of NPI-0052, (ii) all three proteasome activities in liver, kidney, lung, and spleen recovered within 24 h after treatment with NPI-0052 and (iii) inhibition of CT-L, C-L and T-L activities increased in tumour after the third compared to the first NPI-0052 treatment. For example, all three activities were inhibited approximately 70-80% at 24 h post-third dose vs. 25-60% post single dose. In agreement with our prior studies (Chauhan et al, 2005) , other normal tissues had the ability to recover proteasome activities even after exposure to three doses of NPI-0052. Importantly, no significant inhibition of proteasome activity 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55 was noted in brain tissue at any time point after either a single or three doses of NPI-0052, suggesting that NPI-0052 does not cross the blood-brain barrier at the efficacious dose tested.
Levels of
3 H-NPI-0052 in tumour, blood and kidney of MM.1S-tumour bearing mice
We next examined the distribution of 3 H-NPI-0052 in selected organs of MM.1S-tumour bearing mice following the administration of 3 H-NPI-0052 (0AE15 mg/kg or 0AE45 mg/m 2 ; i.v.). The maximal 3 H-NPI-0052 levels occurred within 10 min after drug administration in the tumour, and exhibited a similar timecourse in the kidney (Fig 3A) . The mean drug level observed in the tumour supernatant equated to 2AE924 ng/g tumour tissue (8AE8 nmol/l), which was greater than the 50% growth inhibitory concentrations of NPI-0052 for MM.1S cells (IC 50 : 7 nmol/l), as previously reported (Chauhan et al, 2005) . Our prior study also showed that these concentrations of NPI-0052 markedly blocked all three proteasome activities (Chauhan et al, 2005) . Importantly, in the present study as well, these drug levels were sufficient to induce anti-tumour activity (Fig 4A) and trigger proteasome inhibition in tumours (Figs 1, 2 and 5A ).
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Distribution of 3 H-NPI-0052 in Sprague-Dawley rats
To confirm our findings in MM.1S tumour bearing mice, non-tumour bearing rats were injected with 3 H-NPI-0052 (0AE1 mg/kg or 0AE6 mg/m 2 ; i.v.), and subjected to QWBA. In agreement with our data using MM.1S-tumour-bearing mice, high levels of 3 H-NPI-0052 (total radioactivity) were noted in kidney (Fig 3B) . Lung, liver and spleen also 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55 exhibited relatively high levels, whereas radioactivity was very low/undetectable in the brain, spinal cord and eye.
In vivo anti-MM activity of NPI-0052
Having shown that NPI-0052 targets the proteasome in xenografted tumours, we next determined whether the same dose and schedule of NPI-0052 triggered anti-tumour activity. MM.1S-tumour bearing mice were injected with NPI-0052 (0AE15 mg/kg; i.v.) twice a week for 3 weeks, and tumour volume was measured. In agreement with our prior studies (Chauhan et al, 2005) , NPI-0052 treatment significantly decreased tumour growth relative to untreated vehicle-treated control mice (Fig 4A; P =0 AE005) . NPI-0052 treatment was not associated with any toxicity, because no differences in body weight and overall appearance were noted (data not shown). Importantly, the anti-MM activity of NPI-0052 was evident as early as day 5-7, when significant proteasome inhibition was observed in the tumours (Fig 4A) .
To determine whether in vivo anti-MM activity of NPI-0052 was due to apoptosis, xenografted tumours were harvested from mice, and paraffin-embedded sections were examined for apoptosis by both immunostaining and immunoblot analysis for caspase-3 activation. Tumour sections from NPI-0052-treated mice showed increased numbers of caspase-3 positive cells compared to untreated control mice (Fig 4B) . Moreover, immunoblot analysis of tumour lysates confirmed that NPI-0052 triggered caspase-3 cleavage in vivo (Fig 4C) . Importantly, examination of tumour lysates from NPI-0052-treated mice showed robust cleavage of poly(ADP)-ribose polymerase (PARP), a hallmark of apoptosis (Fig 4C) .
Our data therefore showed that either a single or three doses of NPI-0052 inhibited proteasome activity in MM xenografted tumours. For efficacy studies, we utilized a more frequent dosing schedule i.e., twice a week for 3 weeks, and we therefore next questioned whether proteasome activity was similarly affected by this dosing schedule. Tumours excised 3 h after the last dose administration were examined for CT-L, C-L and T-L proteasome activity. Treatment with NPI-0052 (0AE15 mg/kg), but not with vehicle alone, significantly inhibited all three proteasome activities (Fig 5A) , confirming that NPI-0052-induced anti-MM activity in vivo (Fig 4) is associated with inhibition of proteasome activity in tumours.
Prior studies have shown a role for the endothelial reticulum (ER) during bortezomib-induced apoptosis (Mitsiades et al, 2002; Landowski et al, 2005; Obeng et al, 2006; Chauhan et al, 2008) . Analysis of tumour lysates from NPI-0052-treated mice showed induction of endoplasmaic stress-response, evidenced by upregulation of CHOP/GADD153, phospho-eIF2a, Bip, and Hsp70, providing in vivo evidence of ER stress-related signalling during NPI-0052-triggered cytotoxicity (Fig 5B) . Various prior studies have linked proteasome inhibition with alterations in nuclear factor-kappa B (NF-jB) (Adams et al, 1999; Mitsiades et al, 2002; Chauhan et al, 2005) . We next examined whether NPI-0052-triggered proteasome inhibition in vivo was associated with changes in NF-jB. Analysis of tumour versus normal tissue (kidney) lysates from NPI-0052-treated mice showed stabilization of IjBa levels (Fig 5C) . Importantly, the IjBa levels returned to baseline in normal tissue, but not tumours, after 24 h treatment with NPI-0052-the kinetics that correlates with recovery of proteasome activity in normal tissue versus tumours (Fig 2) . Together, these data provide evidence for a modulation of a proteasome substrate NF-jB by NPI-0052 in vivo.
Besides proteasome inhibition and induction of ER-Stress signalling, anti-angiogenic activity of NPI-0052 may also contribute to its anti-MM activity in vivo. We therefore next evaluated paraffin-embedded sections of xenografted tumours harvested from NPI-0052-treated and control mice for Factor VIII staining, a marker of angiogenesis. As seen in Fig 5D , NPI-0052 dramatically decreased the number of Factor VIIIpositive cells compared to treatment with vehicle alone.
Discussion
Bortezomib (Velcade TM ) therapy has proven successful for the treatment of relapsed/refractory, relapsed and newly diagnosed multiple myeloma (MM) (Hideshima et al, 2001; Orlowski et al, 2002; Richardson et al, 2003 Richardson et al, , 2005 San Miguel et al, 2008) ; however, prolonged treatment can be associated with toxicity and development of drug-resistance Richardson et al, 2006 Richardson et al, , 2007 . Our recent study showed that the novel proteasome inhibitor NPI-0052 (Feling et al, 2003) induces apoptosis in MM cells resistant to conventional and bortezomib therapies (Chauhan et al, 2005) . The mechanism whereby NPI-0052 overcomes bortezomib-resistance includes the ability to block all three proteasome activities (CT-L, T-L, and C-L) compared to bortezomib, which predominantly inhibits CT-L activity. Additionally, NPI-0052-induced MM cell apoptosis is more dependent on caspase-8-than caspase-9-mediated signalling whereas, bortezomib-triggered cell death requires both caspase-8 and caspase-9 signalling pathways. Importantly, in contrast to bortezomib, NPI-0052-mediated proteasome inhibition is irreversible as evident in PWB but rapidly recovers in normal tissues including PBMC (Chauhan et al, 2005) . These distinctions between NPI-0052 and bortezomib, in part, may account for the ability of NPI-0052 to overcome bortezomib-resistance. NPI-0052 is orally active (Chauhan et al, 2005) . In murine tumour model studies, NPI-0052 is well tolerated and prolongs survival, with significantly reduced tumour recurrence. These findings provided the basis for an ongoing phase-1 clinical trial in MM. In the present study, we utilized our human MM xenograft mouse model to study the pharmacodynamic profile of NPI-0052, assessed by alterations in the proteasome activities as well as distribution of 3 H-NPI-0052 in various tissues. We showed that NPI-0052 rapidly distributed from the vascular compartment to various organs and tumours, evident by inhibition of CT-L, C-L, and T-L proteasome activities. These findings are consistent with prior studies (Chauhan et al, 2005; Macherla et al, 2005) demonstrating the ability of NPI-0052 to target all three 20S proteasome activities. Of note, the kinetics of proteasome inhibition varied between tumours and other tissues. For example, the onset of NPI-0052-induced proteasome inhibition was rapid (within 10 min) in most tissues other than tumour, which occurred at 1 h and was maximal at 24 h. Intravenous injection of either single or three doses of NPI-0052 (0AE15 mg/kg) inhibited proteasome activities in peripheral organs, whereas it did not inhibit proteasome activity in the brain, suggesting that NPI-0052 does not cross the blood-brain barrier at this dose and schedule, which is supported by the QWBA study in rats. Analytical studies demonstrated that after i.v. injection, 3 H-NPI-0052 rapidly entered the tumour as the parent compound and was present in concentrations consistent with proteasome inhibition and tumour cell death. Following i.v. administration the distribution profile of 3 H-NPI-0052 in rats appeared similar to that in MM.1S-tumour bearing mice. Previous studies using bortezomib have also shown rapid clearance and broad tissue distribution in a prostate xenograft tumour model (Adams et al, 1999) . Our data show that the duration of proteasome inhibition is more sustained in tumours and PWB (>24 h) than in other tissues. Our prior report showed that a single dose of NPI-0052 (0AE15 mg/kg) in rats led to significant proteasome inhibition in PWB, which slowly recovered by Day 7 (Chauhan et al, 2005) . This may be due to the irreversible covalent binding of NPI-0052 to active proteolytic sites and/or the inability of erythrocytes to generate new proteasomes. Studies using the reversible inhibitor bortezomib showed that proteasome activity recovered after 48 h in blood (Chauhan et al, 2005) , suggesting that reversible nature of proteasome inhibitor plays a role in proteasome activity recovery in blood.
In tumours, NPI-0052 inhibited all three proteasome activities by 24 h after a single treatment (60% for CT-L; 24% for T-L, and 49% for C-L activity); moreover, administration of three doses enhanced inhibition of proteasome activities by 24 h (83% for CT-L; 70% for C-L; and 70% for T-L). As noted above, sustained inhibition of proteasome activity may be due to the irreversible property of NPI-0052; however, a longer half-life of the proteasome in tumours versus normal tissues remains possible. Interestingly, NPI-0052-triggered inhibition of proteasome activity in liver, spleen, kidney, and lungs clearly recovered by 24 h, suggesting that de novo and rapid proteasome synthesis may account for the recovery of proteasome activity in these tissues.
Our efficacy studies showed that i.v. injection of 0AE15 mg/ dose (0AE45 mg/m 2 ) given twice weekly for 3 weeks significantly
Blackwell Publishing Ltd, British Journal of Haematology reduced tumour growth, and was well tolerated. Importantly, this potent in vivo anti-MM activity of NPI-0052 was associated with significant inhibition of CT-L, C-L, and T-L proteasome activities (60-80% inhibition), suggesting that frequent dosing of NPI-0052 allows for sustained proteasome inhibition. Furthermore, these in vivo findings, coupled with our previously published in vitro data showing minimal toxicity of NPI-0052 against normal cells (Chauhan et al, 2005) , confirm that MM cells are more sensitive to proteasome inhibition than normal cells. Although the primary target for NPI-0052 is the proteasome, our in vitro studies showed that NPI-0052-induced apoptosis in MM cells is associated with loss of mitochondrial membrane potential, increase in O 2 ) production, release of cytochrome-c/Smac, and activation of caspases-8, -9 and -3 (Chauhan et al, 2005) . Biochemical and genetic evidence showed that NPI-0052, in contrast to bortezomib, relies more on the FADD-caspase-8-mediated cell death signalling pathway (Chauhan et al, 2005) . In agreement with these in vitro results, IHC staining of xenografted tumours from NPI-0052-treated mice showed robust PARP cleavage and caspase-3 activation. Importantly, in the present study, we also showed that NPI-0052 upregulated expression of ER-stress related proteins (CHOP/GADD153, phospho-eIF2a, Bip), and Hsp70 in tumours, providing in vivo evidence for the role of ER signalling during NPI-0052-triggered cytotoxicity. Finally, results from the Factor VIII immunostaining of tumour sections confirmed the anti-angiogenic activity of NPI-0052 associated with anti-MM activity of NPI-0052 in vivo.
Collectively, our findings represent the first attempt to correlate the pharmacodynamic effects of NPI-0052 with its cytotoxic effects against MM in vivo in tumour and normal tissues. Importantly, was well tolerated at the dose and schedule examined. NPI-0052 blockeed all three proteasome activities (CT-L, C-L, and T-L) by >70% in most tissues without significant toxicity. Early results from a phase-1 clinical trial of NPI-0052 in patients with relapsed and relapsed/refractory MM have been reported to demonstrate potential clinical benefit at doses which are well tolerated . Proteasome inhibition in PWB of treated patients showed a drug-dependent CT-L inhibition, with inhibition up to 28% observed at 0AE025 mg/m 2 dose.
Complete inhibition of CT-L proteasome activity has been observed at MTD doses (0AE7 mg/m 2 ) in other clinical trials, without evidence of neuropathy or myelosuppression. In MM, dose escalation and scheduling effects are currently ongoing to define the dose-limiting toxicity and MTD, and in order to define a recommended phase-2 dose (RP2D) for evaluation in patients with advanced MM.
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